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MIF homologues from a filarial nematode parasite synergize
with IL-4 to induce alternative activation of host
macrophages
Lidia Prieto-Lafuente, William F. Gregory, Judith E. Allen, and Rick M. Maizels1
Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, United Kingdom
Abstract: Macrophage migration inhibitory fac-
tor (MIF) is a highly conserved cytokine considered
to exert wide-ranging, proinflammatory effects on
the immune system. Recently, members of this
gene family have been discovered in a number of
invertebrate species, including parasitic helminths.
However, chronic helminth infections are typically
associated with a Th2-dominated, counter-inflam-
matory phenotype, in which alternatively activated
macrophages (AAMs) are prominent. To resolve
this apparent paradox, we have analyzed the activ-
ity of two helminth MIF homologues from the filar-
ial nematode Brugia malayi, in comparison with
the canonical MIF from the mouse. We report that
murine MIF (mMIF) and Brugia MIF proteins in-
duce broadly similar effects on bone marrow-de-
rived mouse macrophages, eliciting a measured
release of proinflammatory cytokines. In parallel,
MIF was found to induce up-regulation of IL-4R on
macrophages, which when treated in vitro with MIF
in combination with IL-4, expressed markers of
alternative activation [arginase, resistin-like mole-
cule  (RELM-) or found in inflammatory zone 1,
Ym-1, murine macrophage mannose receptor] and
differentiated into functional AAMs with in vitro-
suppressive ability. Consistent with this finding, re-
peated in vivo administration of Brugia MIF in-
duced expression of alternative macrophage acti-
vation markers. As mMIF did not induce RELM-
or Ym-1 in vivo, alternative activation may require
components of the adaptive immune response to
Brugia MIF, such as the production of IL-4.
Hence, MIF may accentuate macrophage activa-
tion according to the polarity of the environment,
thus promoting AAM differentiation in the pres-
ence of IL-4-inducing parasitic helminths. J. Leu-
koc. Biol. 85: 844–854; 2009.
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INTRODUCTION
Mammalian migration inhibitory factor (MIF) was among the
first immune system cytokines to be discovered as a soluble
factor released from activated lymphocytes that inhibited ran-
dom migration of macrophages [1, 2]. The designation of mac-
rophage MIF has endured, although MIF is now recognized as
being highly pleiotropic in regulation of innate and adaptive [3,
4] immune cell populations, as well as cells of the neuroendo-
crine system. Equally, MIF is notable for its production by a
wide range of cell types, locally by macrophages [5], T cells [3],
and eosinophils [6], as well as systemically by the anterior
pituitary gland [7].
There are compelling data from a variety of systems that MIF
acts in a strongly proinflammatory manner [8, 9]. In vitro,
exogenous MIF elicits the release of IL-6, IL-8, TNF-, and
endogenous MIF secretion from human monocytes and mouse
macrophages. In vivo, MIF synergizes with LPS to accentuate
toxic shock [7]. Most strikingly, MIF deficient (MIFo/o) mice
survive the normally lethal administration of LPS or staphylo-
coccal enterotoxin [10]. Similarly, MIFo/o animals do not suc-
cumb to 2,4,6-trinitrobenzene sulfonic acid-induced colitis
[11], demonstrating that MIF is required in sustained inflam-
matory disease as well as in the acute setting of septic shock.
Not only Th1-type but also Th2-dominated allergic responses
are diminished in the absence of MIF [12, 13], which may be
essential in resistance to bacterial infection. Not only does it
up-regulate innate pattern receptors such as TLR4 [14], but
MIFo/o mice die following low-dose Salmonella typhimurium
infection [15]. The same MIF-deficient animals are more sus-
ceptible to a protozoan (Leishmania major [16]) and helminth
(Taenia crassiceps [17]) infection, albeit a helminth infection
where parasite clearance is mediated by proinflammatory cyto-
kines [18]. Against this background of a spectrum of immune
reactivities promoted by MIF, it is perhaps suprising that many
tumors also produce this cytokine [19], and in the setting of
cancer, MIF may act in an immunosuppressive capacity [20–24].
MIF has two unusual biochemical properties. First, it en-
codes no signal sequence [25] but is secreted by an alternative
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route requiring an ABC-containing transporter protein [26].
Second, MIF is unique in combining cell-stimulatory activity
(cytokine) with two enzymatic activities within a relatively
small protein [25], namely a tautomerase, which is dependent
on Pro-2 [27], and an oxidoreductase, dependent on cysteine
residues 57 and 60, forming a thioredoxin-like motif [28]. The
signaling pathway for MIF-induced effects has proven more
enigmatic [4, 29, 30]. CD74 (invariant chain) is one receptor
for MIF that can, via CD44, activate intracellular MAPK
pathways [31–33]. MIF can also bind the chemokine receptors
CXCR2 and CXCR4, which are expressed on many CD74-
negative cell types, linking it more closely to chronic inflam-
mation such as artherosclerosis [34]. However, in the cyto-
plasm, MIF also binds c-Jun activation domain-binding pro-
tein-1 (Jab1), preventing the latter from activating the
proinflammatory transcription factor AP-1 [35]. Hence, in some
circumstances, MIF can exert an anti-inflammatory effect. Al-
though this activity may require relatively high MIF concen-
trations [30], studies on tumors have suggested that immune
evasion results, directly or indirectly, from high levels of MIF
production [22].
In this context, the discovery of MIF secreted by parasites,
which establish a broadly counter-inflammatory environment
[36, 37], is particularly intriguing. Thus, in the filarial nema-
tode parasite Brugia malayi, two MIF homologues are present,
Brugia (Bm)-MIF-1 and -2, with, respectively, 40% and 27%
identity with the mammalian proteins [38, 39]. As these levels
of amino acid identity were relatively low, it was possible that
the parasite homologues were functionally different from the
mammalian ones. We therefore compared Brugia and mamma-
lian MIFs, to test whether parasite proteins would antagonize
the mammalian ones or even stimulate host cells in a different
way altogether. Surprisingly, tests with human monocytes
showed that like human MIF (hMIF), parasite MIF proteins
induce a proinflammatory profile of cytokines such as TNF-,
IL-8, and even hMIF [39]. Thus, parasite MIF induces host
cells to release more MIF of endogenous origin. Moreover,
Brugia MIFs were found to be biochemically and structurally
similar to mammalian MIFs. Bm-MIF-1/2 have high levels of
dopachrome tautomerase enzyme activity, although some sig-
nificant differences in substrate preference were observed [39].
The three-dimensional crystal structure of Bm-MIF-2 [39], like
that of hookworm MIF [40], is remarkably similar between host
and parasite molecules. It should also be noted that Bm-MIF-2
has neither the Cys-57 nor -60 associated with oxidoreductase
activity but retains similar in vitro cytokine activity to Bm-
MIF-1 in which these residues are conserved [39].
The synergy between MIF and LPS in the induction of
TNF- and IL-6 suggests a role in the classical activation of
macrophages by microbial products and proinflammatory cyto-
kines. Yet, over recent years, it has become apparent that in
helminth infection, macrophages develop a distinct activation
state that is dependent on the Th2 cytokines, IL-4, and IL-13
[36, 41–44]. These “alternatively activated macrophages”
(AAMs) are characterized by high-level transcription of argi-
nase type I, the chitinase-like molecule Ym-1 and resistin
family member, resistin-like molecule  {RELM-; or found in
inflammatory zone 1 (Fizz1) [45–48]}, and surface expression
of the C-type lectin family member mannose receptor (MR)
[49]. Brugia infection of mice has proved a valuable model for
the in vivo study of alternative macrophage activation, as large
numbers of AAMs arise within 7 days of live adult Brugia
transplantation into the peritoneal cavity. These macrophages
suppress proliferation of a range of target cells through a
contact-dependent mechanism that is dependent on IL-4 [46,
47, 50–52].
Because of the prominence of these novel macrophages in
the response to Brugia and the known activity of MIF for
macrophages, we injected Bm-MIF-1 (free of detectable LPS)
nine times over 3 weeks into the peritoneal cavity [45]. The
infiltrating population of cells was then tested: Although the
macrophages were not directly suppressive, they expressed
Ym-1, and a threefold rise in eosinophils was also observed,
consistent with the description of Ym-1, as an eosinophil
chemotactic factor [53] and the recent evidence that AAMs are
involved in recruiting eosinophils to peripheral sites [54].
Significantly, such changes were not observed with Bm-
MIF-1G mutant recombinant protein nor with LPS at a dose
corresponding to that which would have been undetectable in
the original MIF-1 preparation.
These findings have posed a central paradox: Why should
parasites that appear masterful at avoiding inflammatory attack
[36, 55, 56] secrete molecules that are thought to amplify
inflammation? In this study, we questioned whether parasite
MIFs do in fact differ functionally from mammalian cytokines
and in particular, how in the context of a parasite-induced Th2
response, MIF exposure can promote the generation of AAMs.
MATERIALS AND METHODS
Bone marrow-derived macrophages (BMDM)
BM cells were taken from femoral bones of C57BL/6 mice and cultured in
DMEM supplemented with 20% FCS, 2 mM L-glutamine, 0.25 U/ml penicillin,
100 g/ml streptomycin, and 20% L929 cell-conditioned medium as a source
of M-CSF. At Day 6, culture plates were washed once with PBS at 37°C to
remove nonadherent cells before detaching adherent macrophages with 3 mM
EDTA and 10 mM glucose in PBS. Macrophages were then replated in 24- or
96-well plates at the appropriate concentration and allowed to adhere overnight
prior to treatment. Cell preparations were typically 85% F4/80-positive.
Recombinant MIFs (rMIFs)
The pET29 system (Novagen, San Diego, CA, USA) was used for bacterial
expression of recombinant 6-His-tagged proteins as described previously [39].
Mouse MIF (mMIF) was produced in the same system, using a coding insert
provided generously by Dr. Patrick Skelly (Harvard University, Cambridge,
MA, USA). mMIF-G was constructed by altering the codon for Pro-2 within a
PCR primer as described [39]. Plasmid DNA was transformed into Escherichia
coli BL21(DE3), single colonies were grown at 37°C, and recombinant protein
expression induced in the presence of 1 mM isopropylthiogalactoside. Recom-
binant proteins were recovered by sonication in 20 mM Na2HPO4/NaH2PO4,
pH 8.0, 0.5 M NaCl, 10 mM imidazole, followed by nickel-chelating affinity
chromatography on an A¨KTAprime system (Amersham Biosciences, Piscat-
away, NJ, USA). To avoid effects as a result of any endotoxin contamination,
recombinant proteins were treated with 20 g/ml Polymixin B sulfate (Sigma
Chemical Co., St. Louis, MO, USA) for 30 min at 37°C prior to use in cellular
assays.
In vitro stimulation
For in vitro stimulation, 106 macrophages were incubated with 10 g/ml each
recombinant protein. For some experiments, macrophages were cotreated with
IL-4 at different concentrations (0.2–100 ng/ml), as indicated in the text.
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In vivo stimulation
BALB/c mice or IL-4R/ mice on the BALB/c background were injected
i.p. with 1 g/ml each recombinant protein, diluted in PBS (pyrogen-free,
Sigma Chemical Co., D8537). Control animals were injected with PBS alone.
Injections were given twice a week for a total of nine injections.
Flow cytometry for surface markers
Cells were stained at 24 h post-treatment with the following reagents for
surface activation markers: MHC-II (clone 2G9, rat IgG2a), CD40 (clone 3/23,
rat IgG2a), CD80 (clone 16-10A1, Armenian hamster IgG2), and CD86
(clone GL1, rat IgG2a; all from Becton Dickinson, San Jose, CA, USA; used at
1:200 dilution) and F4/80 (clone BM8, rat IgG2a, Caltag, South San Francisco,
CA, USA). Appropriate isotype controls with same fluorophore were used
(Becton Dickinson and Caltag). Cells were analyzed using a FACSCaliber
(Becton Dickinson) and FlowJo software, Version 4.5.9.
Cytokine ELISAs
Supernatants were collected for cytokine measurement by sandwich ELISA;
IL-6 (capture: MP5-20F3; detection: MP5-32C11; top standard: 100 ng/ml),
IL-10 (capture: JES5-2A5; detection: SXC-1; top standard: 10 ng/ml), IL-12p40
(capture: C15.6; detection: C17.8; top standard: 200 ng/ml), and IL-12p70
(capture: 9A5; detection: C17.8; top standard: 10 ng/ml) were from PharMin-
gen (San Diego, CA, USA), and TNF- (DY410; top standard: 2 ng/ml) was
from R&D Systems (Minneapolis, MN, USA).
Western blot
Samples were mixed with 4 SDS sample buffer (Invitrogen, Carlsbad, CA,
USA) containing 2-ME. Samples were heat-denatured and resolved using
precast 10% gradient Bis-Tris-NuPAGE gels (Invitrogen), which were trans-
ferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA), blocked
with 5% milk in TBS–0.1% Triton X-100–0.05% Tween 20 (TBSTT), followed
by incubation with the appropriate antibodies. Anti-rMIF mouse polyclonal
serum, raised by immunization of MIF-deficient mice with recombinant pro-
tein, was used at a 1:200 dilution in 5% milk TBSTT, followed by total
anti-mouse IgG-HRP conjugate (Dako, Carpineteria, CA, USA) at 1:2000
dilution. ECL substrate (Amersham Biosciences) was used for detection.
RNA extraction and real-time PCR
Following treatment, 1  106 macrophages were collected in 1 ml TRIzol
(Invitrogen), and RNA extraction was performed following the manufacturer’s
protocol, transcribing 1 g RNA using Moloney murine leukemia virus RT
(Stratagene, La Jolla, CA, USA). Ym-1, RELM, Arginase-1, inducible NO
synthase (iNOS), murine macrophage MR (mMMR), IL-4R, and IFN-R1
RNA levels were measured by real-time PCR using LightCycler (Roche
Molecular Biochemicals, Indianapolis, IN, USA) or Chromo4 (Genetic Re-
search Instrumentation Ltd., UK) real-time PCR machines. -Actin or GAPDH
were used as reference genes. Primer sequences are given in Table 1.
LightCycler PCR amplifications were carried out in 10 l, containing 1 l
cDNA, 4 mM MgCl2, 0.3 M primers, and the LightCycler-DNA SYBR Green
I mix (Roche Molecular Biochemicals). Ym-1 was amplified using the following
conditions: 30 s denaturation at 95°C, 5 s annealing of primers at 63°C, and
12 s elongation at 72°C for 40–60 cycles. The fluorescent DNA-binding dye
SYBR Green (Roche Molecular Biochemicals) was monitored after each cycle
at 85°C. For all other primer pairs, the annealing temperature was 55°C, and
SYBR Green fluorescence was monitored at 86°C. Chromo4 PCR reactions
were carried in 10 l containing 1 l cDNA, 0.3 M primers, and SYBR
Green Supermix-uracil DNA glycosylase (Invitrogen). The following conditions
were used: 15 min hot start at 95°C, followed by denaturation at 95°C for 20 s,
primer annealing at 55°C for 20 s, and elongation at 72°C 20 s for 50 cycles.
The fluorescent DNA-binding dye SYBR Green was monitored after each cycle
at 80°C. Expression levels were estimated using the absolute quantitation
method by comparison with a standard curve generated from a pool of all
samples diluted appropriately. Relative expression of the gene of interest was
then calculated as the ratio to a housekeeping gene that remained unaltered
after treatment. For some experiments, fold-increase over untreated macro-
phages was calculated.
Suppression assay
BMDM were treated with different MIF proteins in the absence or presence of
20 ng/ml IL-4 for 24 h. After this time, supernatants were removed, and EL4
cells were then added at a ratio of 1:10 macrophages, and cells were cocultured
for a further 72 h when proliferation was measured by tritiated-thymidine
incorporation.
Anti-MIF mAb production
BALB/c mice were immunized on Day 0 with 100 g alum-precipitated
Bm-MIF-1 and subsequently challenged i.v. with 1 g protein on Days 28–30.
On Day 31, splenocytes were recovered and fused with SP2 myeloma cells. On
Day 7 after fusion, cells were screened against recombinant protein by ELISA.
Cells from positive wells were cloned by limiting dilution in 96-well plates.
Cells were screened and cloned a second time, and selected clones expanded
for antibody production. For antibody purification, cells were grown in 500 ml
RPMI supplemented with low IgG FCS in disposable bioreactors (VectraCell
single-use bioreactor system, BioVectra, Canada). Cells were cultured for 3–4
TABLE 1. Primers Used for Real-Time PCR
Primer Position (nt, exon) Sequence
-actin-for 5-TGGAATCCTGTGGCATCCATGAAAC-3
-actin-rev 5-TAAAACGCAGCTCAGTAACAGTCCG-3
ym-1-for 5-TCACAGGTCTGGCAATTCTTCTG-3
ym-1-rev 5-TTTGTCCTTAGGAGGGCTTCCTC-3
RELM-for 5-GGTCCCAGTGCATATGGATGAGACCATAGA-3
RELM-rev 5-CACCTCTTCACTCGAGGGACAGTTGGCAGC-3
arginase-1-for 5-CAGAAGAATGGAAGAGTCAG-3
arginase-1-rev 5-CAGATATGCAGGGAGTCACC-3
inos-for 5-GCATTTGGGAATGTAGACTG-3
inos-rev 5-GTTGCATTGGAAGTGAAGCGTTTC-3
IL-4R-for 5-GCTACAAGCCCTTCCAGAATCC-3
IL-4R-rev 5-ACAATACCAAAGCCCAGGTCATC-3
IFNgR1-for 5-ATGTGGAGCATAACCGGAGT-3
IFNgR1-rev 5-GGTAAGAGGAGCAACCACCA-3
GAPDH-for 5-TTCCAGTATGACTCCACTCACGG-3
GAPDH-rev 5-GCCCTTCCACAATGCCAAAG-3
mMR-for 5-CTCGTGGATCTCCGTCACAC-3
mMR-rev 5-GCAAATGGAGCCGTCTGTGC-3
for, Forward; rev, reverse.
846 Journal of Leukocyte Biology Volume 85, May 2009 http://www.jleukbio.org
weeks to allow maximum antibody production. Supernatants were harvested
and spun down to remove cells. mAb were purified using a protein-G sepharose
column and the A¨KTAprime system (Amersham Biosciences). Antibody was
eluted using 1 M glycine, pH 2.9, into neutralizing buffer (Tris, pH 9). Purified
antibodies were dialyzed against PBS, filtered under sterile conditions, and
frozen for storage.
MIF mAb depletion
MIF recombinant proteins were incubated with 10 excess (w/w) 2F11C9
mAb that recognizes Brugia and mouse homologues for 2.5 h at 4°C. Immu-
nocomplexes were precipitated using protein-G agarose/sepharose beads (Up-
state, Lake Placid, NY, USA), which were spun down, and supernatants were
subjected to a second round of immunoprecipitation to ensure complete protein
removal.
Statistical tests
One-way ANOVA was performed on log-transformed replicate data, and dif-
ferent treatments were compared by Bonferroni post-test using GraphPad
Prism 4 software.
RESULTS
Stimulation of different macrophage populations
by MIFs
To compare the functions of mouse and helminth MIF homo-
logues, we first treated murine BMDM with rMIF proteins for
24 h and assayed cytokine release as a measure of activation.
The three MIF proteins (Bm-MIF-1, Bm-MIF-2, and mMIF)
exerted similar effects in this regard, with IL-12p40 release at
all doses tested (Fig. 1A) and additional IL-10 production at
higher MIF concentrations (Fig. 1B). It was noted that the
tautomerase-deficient mutants Bm-MIF-1G and -2G acted with
similar potency to the wild-type proteins, and the mutant
mMIF-G was greatly attenuated in effect. All MIF products
tested also induced IL-6 (Fig. 1C) production and as has been
noted previously for Bm-MIF-1 and -2 with human monocytes
[39], TNF- (Fig. 1D). Neither IL-12p70 nor IL-23 was pro-
duced at any detectable level (data not shown). Quantitatively,
levels of IL-12p40, IL-10, and IL-6 released were of a similar
magnitude to, but lower than, those elicited by LPS stimulation
and resistant to Polymixin B inhibition. A similar pattern of
cytokine release was observed with thioglycollate-elicited peri-
toneal and purified splenic macrophage populations (data not
shown). Activation was also assessed by flow cytometry, and
although neither mouse nor parasite MIF altered expression of
the costimulatory molecules CD40, CD80, or CD86, a reduc-
tion in MHC-II expression was observed after treatment with
mMIF or Bm-MIF-2 (data not shown). MIF-stimulated macro-
phages were also tested for production of NO by assay of
culture supernatants by the Greiss reaction, but levels were not
found to be significantly above background amounts (data not
shown).
MIF depletion from the recombinant preparations
abolishes cytokine production
To verify that macrophage stimulation was specific for the MIF
proteins, we depleted MIF from each preparation with a mAb
(2F11C9) specific for, and cross-reactive between, mammalian
and parasite MIF proteins (see Materials and Methods). Ali-
Fig. 1. In vitro cytokine release from MIF-stimulated macrophages. (A–C) Seven-day C57BL/6 BMDM were treated with 1, 5, or 10 g/ml rMIF proteins overnight,
and supernatants were harvested for IL-12p40 (A), IL-10 (B), and IL-6 (C) analysis by ELISA. “G” proteins represent P2G site-directed mutants, in which
tautomerase enzyme activity has been ablated by replacement of Pro-2 with Gly. In direct comparisons of macrophages stimulated with 100 ng/ml LPS, MIF proteins
elicited similar or lower responses (e.g., IL-12p40, LPS stimulation 9.0	2.9 ng/ml and 10 g/ml Bm-MIF-1 7.7	3.1 ng/ml; IL-6, LPS stimulation 8.8	3.0 ng/ml
and Bm-MIF-1 4.3	1.1 ng/ml), and responses to MIF were not inhibited by Polymixin B treatment, which ablated responses to LPS completely. (D) TNF- cytokine
release from BMDM stimulated with 10 g/ml rMIF proteins, which (E and F) were removed from the indicated preparations with a specific mAb (clone 2F11C9),
and BMDM were treated with 10 g/ml rMIF or the equivalent volume of the depleted fraction. IL-6 (E) and IL-10 (F) release was measured after 24 h. Data were
analyzed by one-way ANOVA. ***, P 
 0.001, compared with PBS treatment.
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quots were subjected to two rounds of incubation with an
excess of antibody for 2 h at 4°C, following which, immuno-
complexes were removed on protein-G sepharose beads. SDS-
PAGE analysis confirmed that all detectable MIF protein had
been removed by this procedure, and samples no longer con-
taining MIF were unable to stimulate macrophages, as judged
by the abolition of IL-6 (Fig. 1E) and IL-10 (Fig. 1F) responses.
Filarial MIF homologues do not induce
production of endogenous mMIF
As exposure of macrophages to MIF homologues from parasites
might elict secretion of endogenous mMIF, thereby acting
indirectly in these experiments, we probed culture superna-
tants from stimulated macrophages with an antibody specific
for mMIF. We noted a constitutive level of MIF secretion from
unstimulated cells, which was not increased in the presence of
parasite MIF proteins (Fig. 2), indicating that the effects
observed can be attributed directly to parasite MIF homologues
rather than through the murine cytokine.
MIF homologues enhance alternative activation
of macrophages induced by IL-4
We have described previously the ability of Bm-MIF-1, when
administered in vivo, to promote the alternative activation of
macrophages [45]. We first attempted to reproduce this effect
in vitro by incubating MIF homologues with BMDM. As mark-
ers for alternative activation, we measured expression of Ym-1,
RELM-, Arginase-1 [45–48], and mMMR [57] by real-time
PCR. In these experiments, however, no up-regulation of al-
ternative activation marker genes was detected when incubat-
ing macrophages with increasing concentration of parasite MIF
(data not shown), raising the question of whether other factors
present in vivo might be required in our in vitro system. As
macrophage expression of Ym-1, RELM-, and Arginase-1 is
induced by IL-4 in vivo and in vitro [47, 58, 59], we tested the
response of macrophages cultured with MIF in the presence of
increasing concentrations of IL-4. After overnight treatment,
cells were collected in TRIzol for RNA extraction, and expres-
sion levels of Ym-1, RELM-, and Arginase-1 were measured
by real-time PCR. In addition, we assayed iNOS as a marker of
classical macrophage activation. -Actin and GAPDH were
used as reference genes and showed equivalent results.
Figure 3, A–C, shows that although MIF homologues alone
were unable to induce expression of alternative activation
markers, a marked synergy occurred in the presence of IL-4,
reaching an optimal level at 10 g/ml rMIF with 20 ng/ml IL-4.
Interestingly the synergistic effect of the different MIF homo-
logues differed between mammalian and filarial proteins. Al-
though Bm-MIF-1 and -2 preferentially enhanced Ym-1 ex-
pression (6.5- and 14.8-fold over 20 ng/ml IL-4), mMIF with
IL-4 induced higher Arginase-1 levels (17.2-fold increase over
20 ng/ml IL-4 compared with 6.1 and 7.4 induced by Bm-
MIF-1 and Bm-MIF-2, respectively). Perhaps most strikingly,
mMIF alone induced iNOS in macrophages, which in the
presence of IL-4, was abolished in favor of the production of
arginase transcripts (Fig. 3D). Only RELM- showed no clear
Fig. 2. Macrophages were treated with the indicated proteins and superna-
tants collected after 24 h and separated on SDS-PAGE for Western blot
analysis probed with polyclonal antibody to mMIF, which does not cross-react
with parasite MIF (upper panel) or control normal serum (lower panel). Note
that the strong band in mMIF-treated supernatant is a result of residual
recombinant protein in the supernatant reacting with the antibody.
Fig. 3. MIF homologues synergize with IL-4 to induce gene expression characteristic of AAMs. BMDM
were treated with 10 g/ml rMIF in the presence of increasing concentrations of IL-4 for 24 h, following
which, cells were harvested in TRIzol for RNA extraction and analysis by real-time PCR as described in
Materials and Methods. Graphs represent expression levels of (A) Ym-1, (B) RELM- (also known as
Fizz-1), (C) Arginase-1, and (D) iNOS. Data are expressed as fold-increase over untreated macrophages
and are pooled from two independent experiments with similar results.
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synergies with MIF, as this was induced strongly by IL-4 alone
(black line in Fig. 3B).
MIF homologues induce up-regulation of IL-4R
Macrophage alternative activation is dependent on IL-4R [42,
43]. To elucidate whether the mechanism by which MIF en-
hances IL-4 activation involves IL-4R up-regulation, BMDM
were cotreated with 20 ng/ml IL-4 and 10 g/ml MIF and
IL-4R expression measured by RT-PCR. All three MIF ho-
mologues induced IL-4R expression in the absence of IL-4,
although in the case of mMIF, the change did not attain
statistical significance (Fig. 4A). Importantly, treament of
macrophages with IL-4 alone did not raise IL-4R mRNA
levels, and it required the combination of both ligands to
achieve a substantial increase in expression levels; this was
true for all MIF homologues (Fig. 4A). IL-4R induction was
observed in the presence of wild-type and tautomerase-defi-
cient proteins. The synergy between MIF and IL-4 was again
evident in the induction of arginase (Fig. 4B) and of the FMR
(Fig. 4C), which is an additional marker of alternative activa-
tion of macrophages [49]. Arginase and MR levels were ele-
vated in the presence of IL-4 alone but were greatly enhanced
on addition of any of the MIF proteins tested.
In contrast to the strongly synergistic enhancement of IL-
4R in macrophages by MIF proteins, similarly treated cells
did not up-regulate the IFN-R (Fig. 5A). Indeed, a small
reduction in transcript levels appears to accompany MIF ex-
posure (although this did not reach statistical significance), and
IL-4 itself was necessary and sufficient to suppress transcript
levels. IL-4 was also found to inhibit the ability of MIF to
induce proinflammatory IL-6 and IL-12p40 (Fig. 5, B and C),
while having no effect on the macrophage IL-10 response to
MIF proteins (Fig. 5D). As IL-4 alone cannot stimulate IL-10
production, the combination of MIF stimulation and selective
inhibition by IL-4 results in a strongly polarized, counter-
inflammatory outcome.
MIF homologues synergize with IL-4 to suppress
EL4 proliferation
A notable feature of AAMs is their ability to suppress T cell
proliferation, an important characteristic during helminth in-
fection [44, 52, 60, 61]. To test whether MIF homologues are
involved in the induction of this key functional characteristic,
BMDM were treated as before with MIF in the presence or
absence of 20 ng/ml IL-4 overnight. After this time, EL4 cells
were added to cultures at a 1:10 ratio. Cells were cocultured for
72 h, following which, proliferation was measured by thymidine
incorporation (Fig. 6A). Macrophages that had been treated
with any of the MIF proteins alone exerted a small reduction in
the proliferation of EL4 cells in vitro, which did not reach
statistical significance. Similarly, IL-4-treated macrophages
were able to effect only a small reduction in EL4 cell-prolif-
erative activity. However, in the presence of exogenous IL-4,
MIF homologues induced macrophages to be strongly suppres-
sive, effectively blocking EL4 proliferation (Fig. 6B). Up to
75% suppression was observed from macrophages exposed to
Bm-MIF-1, Bm-MIF-2, or mMIF. Suppression was also ob-
served, albeit at a more modest level, when macrophages were
treated with tautomerase-deficient MIF mutants (Fig. 6C).
Brugia MIF but not mMIF induces alternative
activation in vivo
We had demonstrated previously that repeated injection of
Bm-MIF-1 but not Bm-MIF-1G induced macrophage and eo-
sinophil recruitment to the peritoneal cavity, with induction of
Ym-1 as a marker of alternative activation [45]. We chose to
repeat and extend these in vivo experiments to determine
whether the activity of mMIF was comparable with that of
parasite MIF. BALB/c mice were injected i.p. with recombi-
nant protein nine times over a 3-week period. As described
previously, MIF-1 but not MIF-1G induced Ym-1 expression in
macrophages recruited to the peritoneal cavity (Fig. 7A).
Fig. 4. MIF homologues up-regulate expression of IL-4R and MR. BMDM
were treated with 10 g/ml rMIF in the presence or absence of 20 ng/ml IL-4
for 24 h, following which, cells were harvested and analyzed as above for
expression levels of (A) IL-4R, (B) arginase, and (C) MR. Expression levels
are calculated in arbitrary units relative to a housekeeping gene control
(GAPDH). Statistical significances were assessed by one-way ANOVA of
transformed (log) data, including the Bonferroni post-test. *, P
 0.05; **, P

0.01; ***, P 
 0.001, compared with medium alone; , P 
 0.05; , P 

0.01; , P 
 0.001, compared with corresponding group without IL-4.
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Expression of RELM- (Fig. 7B) and Arginase-1 (Fig. 7C) by
Bm-MIF-1-elicited macrophages further supported the conclu-
sion that these cells were alternatively activated. Interestingly,
mMIF showed a tendency to induce a similar expression pro-
file, although not statistically significant, in a pattern consistent
with the in vitro data, in which mMIF-1 was able to promote
Ym-1 and Arginase-1 expression in the presence of IL-4.
Moreover, Bm-MIF-1 and mMIF injections stimulated a peri-
toneal eosinophilia (Fig. 7D), which has previously been asso-
ciated with the presence of Ym-1 [53, 62]. As Bm-MIF-1
induces a more robust expression of key macrophage genes in
vivo than does mMIF, we hypothesize that the parasite proteins
also stimulate an adaptive immune response in vivo, including
the enhancement of IL-4, which amplifies the alternative acti-
vation pathway. Consistent with this proposition, we also noted
IL-4R-deficient mice are unable to produce Ym-1 or
RELM- in response to Bm-MIF-1 challenge in vivo (data not
shown).
DISCUSSION
MIF is an important, if incompletely understood, cytokine with
deep, evolutionary roots [30, 63, 64]. In recent years, expres-
sion of MIF homologues has been reported in a range of
parasitic organisms infective to man, including the protozoa
Plasmodium falciparum [65, 66] and L. major [67], and among
the helminth worms, in the nematodes Brugia [38, 39] and
Trichinella spiralis [68]. In characterizing MIF from helminth
parasites of man, the question arises of whether parasite mol-
ecules mimic or counteract the host cytokine and if the study
of parasite MIF may reveal a hitherto unknown facet of the
mammalian molecule. In now linking Brugia MIF with the
alternative activation of macrophages, we have also shown that
mammalian MIF can, in the context of a type-2 environment,
promote a similar phenotype in host macrophage populations.
MIFs from the filarial nematode Brugia were first character-
ized by their homology with the mammalian protein [38, 39].
Functional studies revealed that Bm-MIF-1 has the ability to
inhibit random migration of human macrophages [38] and that
Bm-MIF-1 and -2 induce cytokine production by these cells
[39]. In addition, the potential role of Bm-MIF-1 in alternative
activation of macrophages during filarial infection was sug-
gested by the observation that in vivo injection of Bm-MIF-1
induced a population of macrophages that expressed Ym-1
[45]. These different observations lead us to hypothesize that
although mammalian MIF is a potent proinflammatory factor,
filarial homologues will activate macrophages to an alternative
phenotype that contributes to counter-inflammation during
Brugia infection.
We first analyzed the direct effect of each parasite MIF
homologue on macrophages in comparison with the host pro-
tein. Neither Brugia nor mMIF significantly altered macro-
phage surface phenotype but were able to stimulate cytokine
production by in vitro-differentiated and ex vivo-purified mac-
rophage populations. We then demonstrated a new function for
MIF in synergizing with IL-4 for the induction of AAM function
and associated gene expression. In addition, the synergy we
report between MIF and IL-4 appears at several levels. For
example, by increasing IL-4R expression, MIF can prime
macrophages to respond to Th2 conditions, and the ability of
MIF to elicit proinflammatory cytokines is ablated in the pres-
ence of IL-4.
Helminth parasites, in common with allergenic stimuli, are
powerful initiators of the type-2 response with prominent IL-4
and IL-13 production [69–71]. These cytokines act through the
IL-4R pathway and STAT-6 phosphorylation to induce an
alternatively activated phenotype characterized by the produc-
tion of Ym-1 [47] and Arginase-1 [43, 58], expression of
Fig. 5. Counter-inflammatory effects of MIF and IL-4 combinations. (A)
Macrophages were incubated for 24 h with 10 g/ml of the indicated proteins
in the absence or presence of IL-4 and levels of expression of IFN-R
measured by real-time PCR relative to a control gene. AU, Arbitrary units.
(B–D) BMDM were treated with 10 g/ml rMIF in the presence or absence of
20 ng/ml IL-4 for 24 h, following which, supernatants were tested for IL-6 (B),
IL-12p40 (C), and IL-10 (D). Data were analyzed by one-way ANOVA. *, P 

0.05; **, P 
 0.01; ***, P 
 0.001, compared with treatment with PBS.
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surface MRs, and the elaboration of functional cell-suppressor
capacity [52]. Our recent work has demonstrated the impor-
tance of IL-4R signaling in the innate induction of Ym-1 and
other alternative activation markers [72]. The present work now
suggests that in Brugia infection, parasite-released Bm-MIF
may be the first stimulus for macrophages to begin alternative
differentiation but that host IL-4 is necessary for this process to
complete.
Although the two Brugia homologues, MIF-1 and -2, are
more potent than mMIF at inducing Ym-1 and RELM- in
vitro and at driving alternative macrophage activation in vivo,
the homologues are broadly equivalent in stimulation of in vitro
Fig. 6. Suppression of proliferation by AAMs treated with MIF and IL-4. (A) Schematic of experimental assay; wells containing 1  105 BMDM were treated (for
24 h) with 10 g/ml each rMIF in the presence or absence of 20 ng/ml IL-4. After this time, 1  104 EL4 cells were added to each well. Cells were cocultured
for a further 72 h, following which, proliferation was measured by thymidine incorporation. (B and C) Proliferative responses of EL4 cells cocultured with
macrophages exposed to MIF proteins with or without exogenous IL-4. (B) Wild-type MIF proteins; (C) MIF-G mutants. Statistical significances were assessed by
one-way ANOVA of transformed (log) data, including the Bonferroni post-test. n.s., Not significant. *, P 
 0.05; **, P 
 0.01; ***, P 
 0.001, compared with
medium (PBS) alone.
Fig. 7. In vivo induction of AAM products and eosinophilia by Bm-MIF-1. (A) Ym-1 transcript levels
measured by RT-PCR on peritoneal cells from mice injected nine times over 3 weeks with PBS or MIF
proteins. (B) RELM- transcript levels in the same peritoneal cell samples. (C) Arginase-1 transcript
levels in the same peritoneal cell samples. (D) Eosinophil induction in the peritoneal cavity of mice
injected nine times over 3 weeks with PBS or MIF proteins. (A–C) Expression levels are calculated in
arbitrary units relative to a housekeeping gene control (-actin). Results are representative of two
experiments with similar results. No NOS-2 transcripts were detected in the same samples. Data were
analyzed by one-way ANOVA, followed by Bonferoni’s post test. *, P 
 0.05; ***, P 
 0.01.
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cytokine production from macrophages. Moreover, mutants
lacking tautomerase enzyme activity are able to induce cyto-
kines and alternative activation in vitro. However, these mu-
tants are inactive in vivo, indicating a lower potency in a
system that we have determined requires nine injections to
achieve a significant effect (W. F. Gregory, unpublished ob-
servations). As MIF-2 lacks the conserved oxidoreductase site
with three conserved cysteine residues in identical positions
(57, 60, and 81), this activity is evidently not required for
immunological effects. Hence, the induction of AAM-related
transcripts is likely to be independent of ERK1/2 phosphory-
lation events, as discussed below, or the production of inflam-
matory cytokines.
A major unresolved issue is how parasite MIF molecules
may signal to host macrophages. It is known that mMIF
activates the MAPK pathway, particularly through ERK1/2
and p38 phosphorylation [32], in a manner that can be
mediated through CD74 and is tautomerase-dependent [31].
However, our studies to date do not indicate that an iden-
tical signaling pathway is in play with respect to the parasite
MIFs, which retain activity in the tautomerase-deficient
mutants, are markedly less potent in activating MAPK phos-
phorylation (unpublished results), and can stimulate CD74-
deficient macrophages (L. Prieto-Lafuente and Elizabeth Bikoff,
unpublished data). Interestingly, it has been shown recently that a
MIF homologue from the hookworm Ancylostoma caninum is
able to bind to the CD74 receptor [40], and similar experiments
with the Brugia molecules would advance our knowledge in
this area.
The concept that MIF can exert anti-inflammatory effects is
certainly not new, as inactivation of Jab1 at the intracellular
level has been predicted to have a down-modulatory impact on
the immune response [30, 35]. At the systemic level, some
striking examples of MIF acting to suppress immunity have
emerged from tumor studies, in which neuroblastoma [22, 24],
melanoma [21], and ovarian cancer [23] cells have each been
found to overexpress MIF, with suppressive consequences for
NK and T cell functions. Mechanistic parallels between im-
mune evasion by tumors and parasites are rarely explored, and
it is possible that further research into MIF in this regard would
be well worthwhile.
In conclusion, our data support the hypothesis that filarial
MIF homologues promote alternative activation of macro-
phages and further argue that mammalian MIF can exert the
same effect under similar circumstances of a strong Th2
environment. The link between Bm-MIF-1 and alternative
activation has been indicated previously [45], and we now
show that Bm-MIF-2 and mouse-MIF can, in the presence of
IL-4, induce macrophage expression of alternative activa-
tion markers in vivo or in vitro. Critically, MIF showed
marked synergy with IL-4, enhancing the expression of
alternative activation markers induced by IL-4 alone, as
well as synergizing to render macrophages suppressive.
Moreover, MIF alone induced IL-4R expression, and IL-
4R levels were strongly up-regulated when IL-4 was
present in the media. Taken together, these data suggest that
MIF is not a unidirectional mediator that always promotes
classical, type-1 inflammation but acts on macrophages
according to the prevailing cytokine environment. In a set-
ting in which innate inflammatory mediators are induced,
such as septic shock, MIF is certainly a powerful amplifier
of inflammation. Our results suggest that in other con-
texts—in the Th2 milieu of helminth infection, as well as,
evidently, allergic inflammation [12, 13]—MIF may accel-
erate the development of type-2 reactivity, including AAMs
and eosinophilia.
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